In value terms, artificial intelligence-related deal activity increased by 50% in Q3 2024 compared with the previous quarter’s total of $2.8m and fell by 100% as compared to Q3 2023. Related deal volume increased by 200% in Q3 2024 versus the previous quarter and was 25% lower than in Q3 2023.
The top-ranked financial advisors supporting these private equity deals in 9M 2024 were Raymond James Financial; Brentwood Capital Advisors; Citizens Financial Group with 2, 1, 1 deals respectively.
The top-ranked legal advisors supporting these private equity deals in 9M 2024 were Bass, Berry & Sims; Choate Hall & Stewart; Morris, Manning & MartinLLP with 1, 1, 1 deals respectively.
For further understanding of GlobalData’s Pharmaceuticals Industry M&A Deals by Top Themes in Q3 2024 – Strategic Intelligence, buy the report here.
From 
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Deals Database tracks global deal activity, including mergers, acquisitions, capital raising, strategic alliances, and licensing agreements. Proprietary analysis is used to group deals into key thematic areas and granular sectors across the world’s largest industries.
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Deal type includes Buyouts and Direct Investments done by Private Equity firms.